Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
17500
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedNet Sales+13.3%
基準 15,448Target17,500million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Operating profit¥383 million → Not disclosed
Net income for the current fiscal year¥313 million → Not disclosed
Only the target level is shown because the current level for comparison was not provided.Key initiatives
01Advance a growth strategy through a quality culture and innovation
02Strengthen value creation capabilities through collaboration among sales, development and production
03Strengthen the global supply system and increase value added in the amino acids business
04Transforming the Chemical Products Portfolio and Pursuing New Businesses
05Expand the CDMO business and drive technological innovation in the pharmaceuticals business
Plan assumptionsSales are expected to increase against a backdrop of strong demand, The impact of the situation in the Middle East on the Company's business is difficult to reasonably quantify at this time, Forward-looking statements are based on information currently available and certain assumptions deemed reasonable at this time
Non-financial targetsIndicator CO2 emissions reduction rate / Target value 50% (versus fiscal 2006) / Timing FY2030, Indicator Male parental leave uptake rate / Target value Maintain at 100% / Timing Not disclosed, Indicator Percentage of women in management positions and on the Board of Directors / Target value Increase / Timing Not disclosed, Indicator Paid leave utilization rate / Target value Increase / Timing Not disclosed, Indicator EcoVadis / Target value Undergo assessment / Timing Not disclosed, Indicator SMETA / Target value Undergo audit / Timing Not disclosed
Risks identified by the company
Geopolitical risks, including the situations in Ukraine and the Middle East
Natural Disaster Risk
Supply chain risks
Rising raw material and energy costs
The possibility that future business performance and other results may differ significantly due to various factors
Reason for revision or withdrawal
The impact of the situation in the Middle East on the Company's business is difficult to reasonably quantify at this time
| Item | Details |
|---|---|
| Plan name | New Medium-Term Management Plan |
| Plan period | 3 years (fiscal 2026–fiscal 2028) |
| Progress against the plan | Formulated |
| Sales Target | ¥15,448 million → ¥17,500 million |
| Operating profit target | ¥383 million → Not disclosed |
| Net income target | ¥313 million → Not disclosed |
| Non-financial targets | Indicator CO2 emissions reduction rate / Target value 50% (versus fiscal 2006) / Timing FY2030, Indicator Male parental leave uptake rate / Target value Maintain at 100% / Timing Not disclosed, Indicator Percentage of women in management positions and on the Board of Directors / Target value Increase / Timing Not disclosed, Indicator Paid leave utilization rate / Target value Increase / Timing Not disclosed, Indicator EcoVadis / Target value Undergo assessment / Timing Not disclosed, Indicator SMETA / Target value Undergo audit / Timing Not disclosed |
| Plan assumptions | Sales are expected to increase against a backdrop of strong demand, The impact of the situation in the Middle East on the Company's business is difficult to reasonably quantify at this time, Forward-looking statements are based on information currently available and certain assumptions deemed reasonable at this time |
| Key initiatives | Advance a growth strategy through a quality culture and innovation, Strengthen value creation capabilities through collaboration among sales, development and production, Strengthen the global supply system and increase value added in the amino acids business, Transforming the Chemical Products Portfolio and Pursuing New Businesses, Expand the CDMO business and drive technological innovation in the pharmaceuticals business |
| Reason for revision or withdrawal | The impact of the situation in the Middle East on the Company's business is difficult to reasonably quantify at this time |
| Risks identified | Geopolitical risks, including the situations in Ukraine and the Middle East, Natural Disaster Risk, Supply chain risks, Rising raw material and energy costs, The possibility that future business performance and other results may differ significantly due to various factors |
| Publication date | 19 May 2026 |
Items this document does not state (13)
Operating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetResults under the previous planSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Under the previous medium-term management plan, the Company achieved its initial numerical targets one year ahead of schedule by advancing key initiatives, despite a challenging operating environment, including higher raw material and energy costs resulting from the worsening situations in Ukraine and the Middle East. Under the new plan, the Company expects sales to increase against a backdrop of strong demand, but has left its profit targets undecided because the impact of the situation in the Middle East on its business is difficult to reasonably quantify at this time.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.